Rapid RP-HPLC method for simultaneous estimation of metformin, pioglitazone, and glimepiride in human plasma

• Autorzy: Sebaiy Mahmoud M. , El-Adl Sobhy M. , Baraka Mohmed M. , Hassan Amira A.

Identyfikatory

DOI

10.1556/1326.2018.00515

• Języki publikacji: EN

Abstrakty

EN

An isocratic reversed-phase high-performance liquid chromatography (RP-HPLC) method has been developed for rapid and simultaneous separation and estimation of 3 antidiabetic drugs, namely, metformin, pioglitazone, and glimepiride, in human plasma within 3 min. Separation was carried out on a MAGELLEN 5U C18 (5 μm, 150 mm × 4.60 mm) using a mobile phase of MeOH–0.025 M KH2PO4 adjusted to pH 3.20 using ortho-phosphoric acid (85:15, v/v) at ambient temperature. The flow rate was 1 mL/min, and the maximum absorption was measured at 235 nm. The retention time of metformin, pioglitazone, and glimepiride was noted to be 1.24, 2.32, and 2.77 min, respectively, indicating a very short analysis time compared to that of other reported methods. Also, limits of detection were reported to be 0.05, 0.26, and 0.10 μg/mL for metformin, pioglitazone, and glimepiride, respectively, showing a high degree of method sensitivity. The method was then validated according to the FDA guidelines for the determination of the three drugs clinically in human plasma, in particular, regarding pharmacokinetic and bioequivalence simulation studies.

Słowa kluczowe

EN

RP-HPLC; metformin; pioglitazone; glimepiride; human plasma

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2020
• Tom: Vol. 32, no. 1
• Strony: 16--21
• Opis fizyczny: Bibliogr. 36 poz., rys., tab.

Twórcy

autor

Sebaiy Mahmoud M.

• Zagazig University, Egypt

autor

El-Adl Sobhy M.

• Zagazig University, Egypt

autor

Baraka Mohmed M.

• Zagazig University, Egypt

autor

Hassan Amira A.

• Zagazig University, Egypt

Bibliografia

• [1] Pasquel, F. J.; Umpierrez, G. E. Diabetes Care 2014, 37, 3124–3131.
• [2] Benoit, V.; Bruno, G.; Nieves, S. G.; Jocelyne, L.; Marc, F.; Fabrizio, A. Clin. Sci. (Lond). 2012, 122, 253–270.
• [3] Jain, D.; Jain, S.; Jain, D.; Amin, M. J. Chromatogr. Sci. 2008, 46, 501–504.
• [4] Umapathi, P.; Ayyappan, J.; Quine, S. D. Trop. J. Pharm. Res. 2012, 11, 107–116.
• [5] Lakshmi, K. S.; Rajesh, T.; Sharma, S. Int. J. Pharm. Pharm. Sci. 2009, 1, 162–166.
• [6] Al Rimawi, F. Talanta 2009, 79, 1368–1371.
• [7] Zarghi, A.; Foroutan, S. M.; Shafaati, A.; Khoddam, A. J. Pharm. Biomed. Anal. 2003, 31, 197–200.
• [8] Hamdan, I. I.; Jaber, A. B.; Abushoffa, A. M. J. Pharm. Biomed. Anal. 2010, 53,1254–1257.
• [9] Song, J. Z.; Chen, H. F.; Tian, S. J.; Sun, Z. P. J. Chromatogr. B: Biomed. Sci. App. 1998, 708, 277–283.
• [10] David, D. M.; Raffaele, P.; Ashish, K. R.; Donatella, P.; Barbara, C.; et al. Pharmacogenomics 2014, 15, 2063–2082.
• [11] Radhakrishna, T.; Rao, D. S.; Reddy, G. O. J. Pharm. Biomed. Anal. 2002, 29, 593–607.
• [12] Ramalingam, P.; Krishna, K. P.; Padmanabha, R. Y.; Chandra, S. G. Malay. J. Pharm. Sci. 2014, 12, 33–46.
• [13] Karthik, A.; Subramanian, G.; Rao, C. M.; Bhat, K.; Ranjithkumar, A.; et al. Pak. J. Pharm. Sci. 2008, 21, 421–425.
• [14] Sane, R. T.; Menon, S. N.; Inamdar, S.; Mote, M.; Gundi, G. Chromatographia 2004, 59, 451–453.
• [15] Saber, A. L. Pak. J. Anal. Environ. Chem. 2008, 9, 118–121.
• [16] Jedlička, A.; Klimeš, J.; Grafnetterova, T. Pharmazie 2004, 59, 178–182.
• [17] Sripalakit, P.; Neamhom, P.; Saraphanchotiwitthaya, A. J. Chromatogr. B 2006, 843, 164–169.
• [18] Sumit, A. G.; Tarkase, K. N.; Mundhe, D. B.; Hajare, P. P. Der Pharm. Chem. 2013, 5, 122–127.
• [19] Chaturvedi, P. K.; Sharma, R. Anal. Lett. 2008, 41, 2133–2142.
• [20] Amanlou, M.; Zarei Ghobadi, M.; Rofouei, M. K.; Saremi, S.; Kebriaeezadeh, A. J. Chem. 2010, 7, 915–921.
• [21] Lakshmi, K. S.; Rajesh, T.; Sharma, S.; Lakshmi, S. Der Pharm. Chem. 2009, 1, 238–246.
• [22] Daniele, S.; Luca, R.; Gian, P. C. S.; Pamela, M.; Marcello, B.; et al. Arch. Med. Sci. 2015, 11, 840–848.
• [23] Lad, N. R.; Bhoir, S. I.; Bhoir, I. C.; Sundaresan, M. Ind. J. Pharm. Sci. 2003, 65, 650–653.
• [24] Bandarkar, F. S.; Khattab, I. S. J. Liq. Chromatogr. Rel. Tech. 2010, 33, 1814–1830.
• [25] Lehr, K. H.; Damm, P. J. Chromatogr. B: Biomed. Sci. App. 1990, 526, 497–505.
• [26] Altinöz, S.; Tekeli, D. J. Pharm. Biomed. Anal. 2001, 24, 507–515.
• [27] Khan, I. U.; Aslam, F.; Ashfaq, M.; Asghar, M. N. J. Anal. Chem. 2009, 64, 171–175.
• [28] Bonfilio, R.; Araújo, M. B.; Salgado, H. J. Braz. Chem. Soc. 2011, 22, 292–299.
• [29] Bhargavi, S.; Suryasagar, G.; Sowmya, D. K.; Ashok, K.; Nama, S. Int. J. Pharm. Sci. Rev. Res. 2013, 21, 131–133.
• [30] Afroz, A.; Haque, T.; Talukder, M. M.; Islam, S. A. Asian J. Pharm. Anal. 2011, 1, 74–78.
• [31] Vinay, P.; Roopa, S. P.; Kshama, D.; Gurinder, S.; Satya, N.; Sarasija, S. Pharm. Methods 2012, 3, 9–13.
• [32] Gadapa, N.; Upendra, M. T. J. Chem. 2013, Article ID 726235, 1–8. http://dx.doi.org/10.1155/2013/726235.
• [33] Anandkimar, R. T.; Gurupadayya, B. M.; Neeraj, S.; Vishwanathan, B. Biochem. Anal. Biochem. 2013, 2, 2.
• [34] US Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation 2001 (http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf).
• [35] Zimmer, D. Bioanal. 2014, 6, 13–19.
• [36] CDER Center for Drug Evaluation and Research, Reviewer Guidance Validation of Chromatographic Methods 1994 (https://www.fda.gov/downloads/drugs/guidances/ucm134409.pdf).

Uwagi

PL

Opracowanie rekordu ze środków MNiSW, umowa Nr 461252 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2020).